Translating In Vitro Antiviral Activity to the In Vivo Setting: A Crucial Step in Fighting COVID-19

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency?utm_campaign=CDER%20New%2006%2F04%2F2020&utm_medium=email&utm_source=Eloqua&elqTrackId=78052426d582450b9b714985c8cfb687&elq=9f66ab842fed4ad882273d547d540736&elqaid=12824&elqat=1&elqCampaignId=10912
https://www.fda.gov/drugs/news-events-human-drugs/translating-vitro-antiviral-activity-vivo-setting-crucial-step-fighting-covid-19?utm_campaign=CDER%20New%2006%2F04%2F2020&utm_medium=email&utm_source=Eloqua&elqTrackId=280195ee954341e69f930c61bd23988f&elq=9f66ab842fed4ad882273d547d540736&elqaid=12824&elqat=1&elqCampaignId=10912

Updated Monday through Friday

• Drug Firm Annual Registration Status
• Drug Firm Annual Registration Status Download File 
• National Drug Code Directory
• NDC Unfinished Drugs Excluded Database File 
• NDC Database Excluded Packages and Products 
• Wholesale Distributor and Third-Party Logistics Providers Reporting  

June 3, 2020

• FDA alerts health care professionals to the temporary absence of warning statement on the vial caps of two neuromuscular blocking agents (New)
• FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency  Guidance for Industry (updated)
• Translating In Vitro Antiviral Activity to the In Vivo Setting: A Crucial Step in Fighting COVID-19 (updated)